Poster SESSIONS
76
Poster, 25 June 2014
P-43-031
A double-blind, placebo-controlled, random-
ized withdrawal study of lurasidone for the
maintenance of efficacy in patients with
schizophrenia
Rajiv Tandon, Gainesville, USA
A. Loebel, D. Phillips, A. Pikalov, D. Hernandez,
Y. Mao, J. Cucchiaro
P-43-032
Risperidone monotherapy influences corti-
cal inhibition in patients with first episode
of schizophrenia: A TMS study
Libor Ustohal, Brno, Czech Republic
R. Prikryl, M. Mayerova, I. Stehnova, H. Prikry-
lova Kucerova, E. Ceskova, T. Kasparek
P-43-035
How does the NSA-4 compare to the NSA-16?
Janet Williams, Hamilton, USA
L. Garzio, D. Osman, D. Popp
P-43-037
Gray matter volume correlates with comt
gene val158met polymorphism in first-epi-
sode treatment-naïve patients with schizo-
phrenia
Bo Xiang, Chengdu, China
P-43-039
A randomized, placebo-controlled repeat-
dose thorough QT study of inhaled loxapine
in healthy volunteers
Paul Yeung, Southeastern, Pa, USA
J. V. Casella, D. A. Spyker
P-43-040
The psychometric properties of night eat-
ing questionnaire in Korean schizophrenic
outpatients
Bo-Hyun Yoon, Naju, Republic of Korea
S.-H. Nam, Y.-H. Sea, J.-H. Song, H.-R. Jeong,
K.-M. Kim
P-43-041
Antipsychotics promote the differentiation
of oligodendrocyte progenitor cells by regu-
lating oligodendrocyte lineage transcription
factors 1 and 2
Yanbo Zhang, Saskatoon, Canada
H. Zhang, J. Wang, X.-M. Li
P-43-042
Differences in weight education programs,
eating habits, energy levels, and physical
activities of patients with schizophrenia or
bipolar disorder treated with olanzapine
across four countries
Tamás Treuer, Budapest, Hungary
W. Montgomery, W. Y. Ye, Z. Kadziola, D. No-
vick, S. Hu Wu, H. B. Haber Xue, J.-F. Joyce
Yeh, I. Ruiz
P-44
POSTER SESSION
17:15–18:45
Hall B
Neurodegeneration C
P-44-002
Pharmacogenetics of angiotensin-converting
enzyme inhibitors in patients with dementia
due to Alzheimer‘s disease
Fabricio Oliveira, São Paulo, Brazil
P. Bertolucci, E. Chen, M. Smith
P-44-003
Neurotranslational analysis of the role of
cholesterol-lowering drugs over cognitive
change in Alzheimer‘s disease
Fabricio Oliveira, São Paulo, Brazil
P. Bertolucci, E. Chen, M. Smith
P-44-004
A case study of primary progressive aphasia,
logopenic type–3 years longitudinal follow-
up in a frontotemporal neurocognitive dis-
order, possible (DSM V)
Marcel-Claudiu Sarpe, Comuna Dumbraveni,
Romania
M. Ladea, M. Bran, D. Prelipceanu
P-44-005
A common target in type 2 diabetes mellitus
and Alzheimer‘s disease (AD)
Mee-Sook Song, Saginaw, USA
C. Learman, T. Hall, A. Clarey, P. Wachowiak,
A. Loftus, M. Field, G. Dunbar
